# Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

> **NCT05970900** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumor of Rectum

## Interventions

- **DRUG:** Imatinib Mesylate
- **PROCEDURE:** Local resection

## Key facts

- **NCT ID:** NCT05970900
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970900, "Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05970900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*